To evaluate spontaneous immunity against p53, we measured serum antibody titers against p53 and NY-ESO-1 proteins in 298 advanced epithelial ovarian cancer patients and 153 healthy individuals by ELISA. This evidence concerns the gene TP53 and ovarian carcinoma.